Healthcare Industry News:  Vbeam laser 

Devices Dermatology

 News Release - April 6, 2006

Laser Treatment Zaps Away Symptoms of Rosacea

Vbeam laser helps millions of Americans suffering from common skin disorder

WAYLAND, Mass.--(HSMN NewsFeed)--April 6, 2006--Rosacea is a common skin disorder that affects 14 million Americans. As a result, most patients with rosacea have lower self-esteem, and tend to avoid public contact or cancel social engagements. With today's technological advances, the redness, appearance of blood vessels, and flushing that occur with rosacea can be removed with pulsed-dye lasers, such as Candela's Vbeam® laser. During Rosacea Awareness Month in April, sponsored by the National Rosacea Society, patients are urged to learn more about effective treatment alternatives now available to help them cope with the serious side effects of this all-too common disorder.

Rosacea Awareness Month is designed to encourage those who may suffer from this widespread condition to seek diagnosis and treatment before it increasingly disrupts their daily lives. Rosacea is characterized by redness on the cheeks, nose, chin or forehead; small visible blood vessels on the face; bumps or pimples on the face; and watery or irritated eyes. Activities such as spending time in the sun, eating spicy food or drinking alcohol can cause embarrassing flare-ups. Treatment with the Vbeam laser allows patients to control rosacea with no downtime.

"The most recent pulsed dye lasers, like Vbeam, have built upon the effectiveness of the older technology by adding the ability to treat rosacea and other vascular conditions without purpura," said Dr. Jeffrey Dover. "Surface vascularity in rosacea is not improved by medications, while pulsed dye laser treatment remains the gold standard for treatment of telangiectasia, redness and flushing due to rosacea. For individuals who previously avoided laser therapy due to downtime related to purpura, now that we can treat without bruising, the Vbeam can be life altering," added Dr. Dover.

Dr. Dover also shared, "With Vbeam treatment, visible blood vessels will disappear very nicely when patients are treated because the wavelength of Vbeam is absorbed well by the hemoglobin, which reduces the chance of damage to surrounding facial tissue."

The Vbeam works by targeting laser energy to the blood vessels. Applying this energy over a longer period of time, in combination with consistent micropulse technology, results in a gentler heating effect, which minimizes purpura (a laser bruise) often seen with earlier versions of pulsed-dye laser technology. As the laser penetrates into the skin, the superficial layers feel thermal effects and the redness dissipates. The Vbeam's Dynamic Cooling Device® (DCD®) emits a cooling spray before each laser pulse, which increases safety and patient comfort. On average, patients who are treated with the Vbeam for rosacea see results after three to four treatments.

"While the cause of rosacea is unknown and there is no cure, medical help is now available that can control the signs and symptoms of this potentially life-disruptive disorder," said Barbara Palombo of the National Rosacea Society. "We hope that those who may be suffering from rosacea will use Rosacea Awareness Month as an opportunity to learn more about this widespread but poorly understood condition."

For information and educational materials on rosacea, write the National Rosacea Society, 800 S. Northwest Highway, Suite 200, Barrington, Illinois 60010, or call its toll-free number at 1-888-NO-BLUSH. Information and materials are also available on the society's Web site at or via e-mail at

For more information on Candela's Vbeam laser, or to see before and after photos of rosacea treatments with Vbeam, visit Contact Candela at 1-800-733-8550 or via email at

About Vbeam Perfecta:

Vbeam Perfecta features Candela's unique consistent micropulse technology which enables advanced laser pulsing capability providing improved clinical efficacy. The new consistent Micropulse technology enables physicians to treat more aggressively using higher fluences, improving treatment efficacy without causing unnecessary downtime for patients. The Vbeam also offers a new pigmented lesion handpiece enabling treatment of brown sun spots and general skin rejuvenation. The addition of indications like pigmented lesions, sun spots and freckles are expanding the already extensive range of clinical applications Vbeam can treat like: facial veins, Rosacea, facial redness, leg veins, scars, stretch marks, hemangiomas and warts. The patented Dynamic Cooling Device (DCD®) is integrated into the ergonomically designed handpiece. The DCD emits a cooling spray milliseconds before each laser pulse, which works to protect and soothe upper layers of the epidermis and provide additional patient comfort.

About Candela:

Candela Corporation manufactures and distributes innovative clinical solutions which enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 17 years ago, and currently has an installed base of 8,500 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer (Male/Female/Handicapped/Veteran). Visit Candela on the Web at or learn more about Vbeam at

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC, including but not limited to, Candela's Annual Report on Form 10-K for the year ended July 2, 2005. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.

Source: Candela

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.